Inhibition or activation of PI3K/Akt signaling

JL Juan Li
LZ Lei Zheng
MY Mi Yan
JW Jing Wu
YL Yongqing Liu
XT Xiaona Tian
WJ Wen Jiang
LZ Lu Zhang
RW Rongmei Wang
ask Ask a question
Favorite

The PI3K inhibitor LY294002 and the PI3K-specific agonist IGF-1 were used to suppress or activate the PI3K/Akt signaling pathway, respectively, in A549/T cells. Cells (1×104 cells/well) were incubated with the following: DMSO; 30 µM FKA for 24 h; LY294002 (10 µM) for 1 h; IGF-1 (12.5 nM) (15) for 1 h; 30 µM FKA for 24 h, followed by LY294002 for 1 h; or 30 µM FKA for 24 h, followed by IGF-1 for 1 h. The protein expression levels of p-Akt (Ser 473) and P-gp were measured by western blot analysis. Each experiment was conducted in triplicates to determine the means and standard deviations (SDs).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A